Dear colleagues.
is well-known use of erythropoietin for neuroprotection HIE during therapeutic hypothermia. It is used in neonates of 35 weeks or more
Unfortunately infants less than 35 weeks also sometimes suffer asphyxia and implementation HIE
What recommendations has the use of erythropoietin in such cases?

But can erythropoietin really be considered standard of care? The most recent review I have found is this one (open access on https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529536/) and it seems rather that larger studies are ongoing.

There is one large US-based study still ongoing (https://clinicaltrials.gov/ct2/show/NCT01378273). A study in Europe (https://clinicaltrials.gov/ct2/show/NCT01732146) is said to be ongoing but "not recruiting" (stopped early?)

As far as I know, NICUs in Sweden do not use erythropoietin for neuroprotection (or, to my knowledge, for treatment of anemia either).

Thank you Stefan for the response and the links provided.
We will continue to monitor the investigations and wait intersnye facts and recommendations

interesting

I also recommend Keith Barrington's comment in his blog on erythropoietin in asphyxia https://neonatalresearch.org/2016/05/09/erythropoietin-for-asphyxia/

It is about the most recent phase II study on this topic published last year.

Thank you for your response and very useful information